Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

esearcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best-selling clinical manual, Essential Psychopharmacology Prescriber's Guide.

Dr. Sheehan has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry, the International Academy for Biomedical and Drug Research, the US Food and Drug Administration, and a research grant reviewer for the National Institute for Mental Health (NIMH). Dr. Sheehan has been invited to give over 1600 lectures in 64 countries throughout the world on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association.

    About Labopharm's Novel Trazodone Formulation and the Market for
    Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rat
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, today ... Services, and Chris Greco, Manager, Comparator and Ancillary ... Active Control Clinical Trials” at the forthcoming US ... the 9th – 10th September, 2014 in Philadelphia, ...
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
(Date:8/28/2014)... over who identify themselves as ,old, feel worse about ... have lower value than younger age groups. , New ... ,Being old and ill, across different countries: social status, ... from the European Social Survey. Respondents, who were all ... health., The researchers found that those living in societies ...
Breaking Medicine News(10 mins):Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Drug shows promise for subset of stage III colon cancer patients 2
... ALEXANDRIA, Va., July 23 The model for,person-centered long ... to testimony submitted today to the US Senate Special ... care that embraces choice,independence and the opportunity for seniors ... Richard Grimes, the President and CEO,of the Assisted Living ...
... had heart trouble, the worse their performance , , WEDNESDAY, July ... heart disease seem to fare worse on measures of cognitive ... disease, the worse the performance in such mental processes as ... the July 23 issue of the European Heart Journal ...
... Three years after Hurricane Katrina devastated parts of the Gulf ... Public Health Project on the Public and Biological Security shows ... they are very prepared if a major hurricane were to ... worries of respondents threatened or hit by Hurricane Katrina are ...
... Cohen Hired As New CEO, ATLANTA, July 23 ... MELCO Investments LLC, a private business and,real estate investment ... a,substantial capital investment in GMCG. Along with the investment, ... leading colon and rectal,surgeons, as its new CEO., ...
... and Medicare Rules Highlighted; a Focus on Preventing ... Hospital-acquired Conditions, LANSING, ... a national leader in clinical risk management,practice and patient safety programs ... for its annual risk,management conference., The conference will take place ...
... the #1 Healthiest City to,Live and Retire In -, ... voice for 50+ Americans and the world,s largest-circulation,magazine with ... ten,healthiest cities to live and retire in with Ann ... Fargo, ND taking the top five rankings.,Featured in the ...
Cached Medicine News:Health News:ASSISTED LIVING: The Model for Person-Centered Long Term Care 2Health News:Coronary Disease Dulls Cognitive Skills 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 3Health News:Hurricane preparedness survey: Worries about drinking water and medical care 4Health News:Hurricane preparedness survey: Worries about drinking water and medical care 5Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5
(Date:8/28/2014)... DUBLIN, Ohio , Aug. 28, 2014 /PRNewswire/ ... rising competition in generics are adding pressure to ... internal resources. Company resources continue to shrink and ... complex. This has led companies to look for ... to commercialization and for keeping approved products on ...
(Date:8/28/2014)... , Aug. 28, 2014   RapidForce , ... announced today a strategic partnership with professional tennis player ... tennis player, Isner wears RapidForce during competitions to help ... competes this week at the 2014 US Open Tennis ... tape, RapidForce Physio Hybrid Shapes are a revolutionary hybrid ...
(Date:8/28/2014)... , Californie, 28 août 2014 ... annoncé aujourd,hui le début des inclusions ... étude  d,exemption des dispositifs expérimentaux (ou ... à évaluer l,innocuité et l,efficacité du ... Le docteur Adam Arthur , ...
Breaking Medicine Technology:4 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 2America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 3America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 4Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
6 mm, 45 degree upwards, detachable....
Aaron 950 is a high frequency desiccator with cut....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: